Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMA1FRM)

Drug Name
PMID28460551-Compound-3 Drug Info
Cross-matching ID
PubChem CID
5083
ChEBI ID
CHEMBL38912
CAS Number
CAS 125314-64-9
TTD Drug ID
D0ZG7E

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Oxidative phosphorylation 2.57 0.00e+0 93/133 (69.92%) ATP6V0E2;ATP6AP1;NDUFA3;...
ECM-receptor interaction 2.06 0.00e+0 80/88 (90.91%) LAMA5;COL6A3;SDC1;...
Glycolysis / Gluconeogenesis 1.99 3.62e-3 56/67 (83.58%) PFKM;ADH1B;ALDOA;...
Complement and coagulation cascades 1.97 5.43e-3 76/85 (89.41%) C3;SERPINA1;F3;...
Arginine and proline metabolism 1.97 4.34e-3 39/50 (78%) PYCR1;ALDH18A1;MAOA;...
Lysosome 1.96 3.62e-3 115/128 (89.84%) ASAH1;ATP6AP1;CTSZ;...
Fatty acid degradation 1.96 3.10e-3 40/43 (93.02%) HADH;ACADM;ACAT1;...
beta-Alanine metabolism 1.92 2.71e-3 25/30 (83.33%) GAD1;ALDH3B1;ECHS1;...
Purine metabolism 1.88 3.62e-3 102/129 (79.07%) GUK1;GUCY1A1;PAPSS1;...
Other glycan degradation 1.82 1.19e-2 13/18 (72.22%) MAN2B2;MAN2B1;MANBA;...
Pentose phosphate pathway 1.82 1.09e-2 25/30 (83.33%) RPIA;PFKM;ALDOA;...
Fatty acid elongation 1.81 1.27e-2 19/27 (70.37%) HACD2;HADH;PPT1;...
D-Glutamine and D-glutamate metabolism 1.81 1.17e-2 5/5 (100%) GLUD1;GLUD2;DGLUCY
Citrate cycle (TCA cycle) 1.81 1.16e-2 30/30 (100%) SUCLG2;PCK1;SDHB;...
Retinol metabolism 1.80 1.09e-2 41/68 (60.29%) ADH1B;RETSAT;DGAT1;...
Alanine, aspartate and glutamate metabolism 1.79 1.09e-2 27/37 (72.97%) ALDH5A1;GLUD1;CAD;...
Proximal tubule bicarbonate reclamation 1.79 1.09e-2 21/23 (91.3%) GLUD1;CA2;GLUD2;...
Valine, leucine and isoleucine degradation 1.79 1.02e-2 42/48 (87.5%) OXCT1;HADH;ACADM;...
Retrograde endocannabinoid signaling 1.78 9.71e-3 118/148 (79.73%) NDUFA3;NDUFA7;GRIA2;...
Primary bile acid biosynthesis 1.76 1.25e-2 15/17 (88.24%) SCP2;HSD17B4;ACOT8;...
Thermogenesis 1.75 1.19e-2 173/232 (74.57%) NDUFA3;NDUFA7;COX7A2L;...
Malaria 1.75 1.23e-2 44/50 (88%) SDC1;SDC2;ACKR1;...
Glycosaminoglycan degradation 1.74 1.32e-2 19/19 (100%) GALNS;GUSB;HEXA;...
Diabetic cardiomyopathy 1.69 2.17e-2 162/203 (79.8%) COL3A1;NDUFA3;NDUFA7;...
ABC transporters 1.69 2.17e-2 37/45 (82.22%) ABCD3;ABCG2;ABCB1;...
Glycosylphosphatidylinositol (GPI)-anchor biosynthesis 1.68 2.17e-2 20/26 (76.92%) PIGT;PIGK;PIGP;...
N-Glycan biosynthesis 1.67 2.29e-2 38/50 (76%) STT3A;DDOST;DAD1;...
Various types of N-glycan biosynthesis 1.66 2.52e-2 26/39 (66.67%) STT3A;DDOST;DAD1;...
Protein export 1.65 2.62e-2 17/23 (73.91%) SPCS1;OXA1L;SRP72;...
Nitrogen metabolism 1.64 2.68e-2 16/17 (94.12%) GLUD1;CA2;CA12;...
FoxO signaling pathway -1.79 3.68e-2 118/131 (90.08%) TGFBR1;CDKN2D;IRS2;...
Spliceosome -1.85 2.45e-2 101/150 (67.33%) ACIN1;DDX42;PPIE;...
Cell cycle -1.99 4.60e-3 110/124 (88.71%) YWHAH;MCM3;MCM6;...
Steroid biosynthesis -2.15 0.00e+0 19/20 (95%) SOAT1;LBR;CYP51A1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Bone marrow
Chronic myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HAP1 CVCL_Y019 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 BRD4 (-) 1 CVCL_SF59 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 CDK4 (-) 1 CVCL_SI36 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 HDAC5 (-) 1 CVCL_SR11 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 ITGA4 (-) 1 CVCL_ST27 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 MAPK8 (-) 1 CVCL_SW99 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PIK3CA (-) 1 CVCL_TD60 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PRKACA (-) 1 CVCL_TG70 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PRKCQ (-) CVCL_TG92 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 RELA (-) 1 CVCL_TI75 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 SRC (-) 1 CVCL_TQ36 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 TP53 (-) 1 CVCL_RJ70 Homo sapiens 0.66uM - 3.33uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
1HAEo- CVCL_0128 Homo sapiens 10uM 24H
NL20 CVCL_0461 Homo sapiens 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Normal (Fibroblast)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HFL1 CVCL_4295 Homo sapiens 10uM 24H
IMR-90 CVCL_0347 Homo sapiens 10uM 24H
WI-38 CVCL_0579 Homo sapiens 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.66uM - 10uM 6H, 24H